Answers are grounded in this paper and cite their sources.
Microbial biopesticides may contain viable microorganisms, requiring safety assessments that address infectivity, pathogenicity, host clearance, and toxicity. However, integrated evaluations of native isolates remain limited. Two microbial biopesticides, Eca9/Mm2 and Eca9/Xd3, formulated using combinations of Bacillus thuringiensis subsp. kurstaki (Eca9) and B. thuringiensis subsp. tenebrionis (Mm2 or Xd3) isolates, were evaluated in female BALB/c mice. Each preparation was administered by oral gavage (100 µL), intranasal instillation (10 µL), and subcutaneous injection (100 µL), with active, heat-inactivated, and shared control groups. Animals were monitored for mortality, clinical signs, and body weight until their designated sampling time points, with a maximum follow-up of 21 days. Microbiological recovery was assessed by heat-selected culturable spore counts in fecal and blood samples following oral and subcutaneous administration and in lung tissue following intranasal administration on days 7, 14, and 21. In intranasally exposed animals, pulmonary TNF-α, MPO, CC16, and ACE2 and serum CRP and PCT were measured by ELISA, while serum ALT, AST activities, and BUN level were determined using an autoanalyzer. Lung histopathology was evaluated by blinded semiquantitative scoring. Each preparation was analyzed separately against the shared control group, without direct statistical comparisons between preparations. No exposure-related mortality or overt clinical signs of toxicity were observed, and percentage body weight gain did not differ from control in any treatment group. Following intranasal administration, pulmonary bacterial load no longer differed significantly from control on day 21 in the Eca9/Mm2 group, whereas it remained significantly elevated in the Eca9/Xd3 group. However, histopathological responses did not parallel bacterial recovery. Active Eca9/Mm2 exhibited significant alveolar septal thickening and interstitial inflammation on day 21 despite pulmonary bacterial recovery no longer differing significantly from control. In contrast, active Eca9/Xd3 produced no significant histopathological changes relative to control; the significant alterations in this preparation were confined to the heat-inactivated form on day 7. These findings indicate that pulmonary bacterial recovery alone is insufficient to establish infection or predict histopathological alterations and that heat-inactivated preparations can elicit biological responses. The results support strain and formulation-specific safety assessments integrating microbiological, biochemical, histopathological, and clinical endpoints.
No takes yet. Share an insight, caveat, or question.
Yıldız et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: